| Title |
Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors
|
|---|---|
| Published in |
Molecular Imaging and Biology, December 2017
|
| DOI | 10.1007/s11307-017-1151-1 |
| Pubmed ID | |
| Authors |
Lucia Baratto, Hossein Jadvar, Andrei Iagaru |
| Abstract |
Gastrin-releasing peptide receptors (GRPRs), part of the bombesin (BBN) family, are aberrantly overexpressed in many cancers, including those of the breast, prostate, pancreas, and lung, and therefore present an attractive target for cancer diagnosis and therapy. Different bombesin analogs have been radiolabeled and used for imaging diagnosis, staging, evaluation of biochemical recurrence, and assessment of metastatic disease in patients with prostate cancer. Recently, interest has shifted from BBN-like receptor agonists to antagonists, because the latter does not induce adverse effects and demonstrate superior in vivo pharmacokinetics. We review the preclinical and clinical literatures on the use of GRPRs as targets for imaging and therapy of prostate cancer, with a focus on the newer developments and theranostic potential of GRPR peptides. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 50 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 18% |
| Researcher | 8 | 16% |
| Student > Master | 7 | 14% |
| Other | 6 | 12% |
| Professor > Associate Professor | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 15 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 10 | 20% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 12% |
| Medicine and Dentistry | 5 | 10% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Agricultural and Biological Sciences | 2 | 4% |
| Other | 5 | 10% |
| Unknown | 19 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 September 2022.
All research outputs
#5,304,202
of 25,611,630 outputs
Outputs from Molecular Imaging and Biology
#122
of 842 outputs
Outputs of similar age
#104,587
of 447,602 outputs
Outputs of similar age from Molecular Imaging and Biology
#1
of 10 outputs
Altmetric has tracked 25,611,630 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 842 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 447,602 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them